$4.62
0.214.76%
At Close: -
$4.85
0.234.98%
After Hours: Jul 18, 8:32 AM EDT
15 minutes delayed
Comments
Loading...
Lantern Pharma
LTRNNASDAQ
Lantern Pharma (NASDAQ:LTRN) Stock, Analyst Ratings, Price Targets, Forecasts
Lantern Pharma Inc has a consensus price target of $11 based on the ratings of 3 analysts. The high is $11 issued by EF Hutton on August 10, 2023. The low is $11 issued by EF Hutton on August 10, 2023. The 3 most-recent analyst ratings were released by EF Hutton on August 10, 2023, June 26, 2023, and May 25, 2023, respectively. With an average price target of $11 between EF Hutton, there's an implied 138.10% upside for Lantern Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Lantern Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar | — | Reiterates | → Neutral | Get Alert |
| 08/10/2023 | Buy Now | 138.1% | EF Hutton | Michael King | → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 138.1% | EF Hutton | Michael King | $11 → $11 | Maintains | Buy | Get Alert |
| 05/25/2023 | Buy Now | 138.1% | EF Hutton | Michael King | → $11 | Assumes | → Buy | Get Alert |
| 05/18/2023 | Buy Now | — | HC Wainwright & Co. | Michael King | — | Initiates | → Neutral | Get Alert |
| 03/21/2023 | Buy Now | 138.1% | EF Hutton | Michael King | → $11 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 138.1% | EF Hutton | Michael King | → $11 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 138.1% | EF Hutton | Michael King | → $11 | Initiates | → Buy | Get Alert |
| 03/11/2022 | Buy Now | 679.22% | HC Wainwright & Co. | Michael King | $34 → $36 | Maintains | Buy | Get Alert |
| 11/02/2021 | Buy Now | 635.93% | HC Wainwright & Co. | Michael King | — | Maintains | Buy | Get Alert |
| 10/07/2021 | Buy Now | 592.64% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Lantern Pharma (LTRN) stock?
The latest price target for Lantern Pharma (NASDAQ:LTRN) was reported by HC Wainwright & Co. on April 25, 2024. The analyst firm set a price target for $0.00 expecting LTRN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lantern Pharma (LTRN)?
The latest analyst rating for Lantern Pharma (NASDAQ:LTRN) was provided by HC Wainwright & Co., and Lantern Pharma reiterated their neutral rating.
When was the last upgrade for Lantern Pharma (LTRN)?
There is no last upgrade for Lantern Pharma
When was the last downgrade for Lantern Pharma (LTRN)?
There is no last downgrade for Lantern Pharma.
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Lantern Pharma (LTRN) correct?
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a reiterated with a price target of $0.00 to $0.00. The current price Lantern Pharma (LTRN) is trading at is $4.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.